Stifel analyst Justin Keywood lowered the firm’s price target on Knight Therapeutics (KHTRF) to C$6.25 from C$6.75 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Reports Q3 2024 Financial Results
- Knight Therapeutics downgraded to Hold from Buy at Mackie Research Capital
- Knight Therapeutics reports Q3 EPS C$0.00 vs. C$0.09 last year
- Knight Therapeutics sees FY24 revenue C$355M-C$365M
- KHTRF Earnings Report this Week: Is It a Buy, Ahead of Earnings?